| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 2936259
[patent_doc_number] => 05190862
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1993-03-02
[patent_title] => 'Chromogenic compounds and the use thereof as enzyme substrates'
[patent_app_type] => 1
[patent_app_number] => 7/776590
[patent_app_country] => US
[patent_app_date] => 1991-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12539
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 260
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/190/05190862.pdf
[firstpage_image] =>[orig_patent_app_number] => 776590
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/776590 | Chromogenic compounds and the use thereof as enzyme substrates | Oct 10, 1991 | Issued |
Array
(
[id] => 2958851
[patent_doc_number] => 05198419
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1993-03-30
[patent_title] => 'Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria'
[patent_app_type] => 1
[patent_app_number] => 7/769766
[patent_app_country] => US
[patent_app_date] => 1991-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 5404
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/198/05198419.pdf
[firstpage_image] =>[orig_patent_app_number] => 769766
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/769766 | Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria | Oct 3, 1991 | Issued |
Array
(
[id] => 2890801
[patent_doc_number] => 05177001
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1993-01-05
[patent_title] => 'In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor'
[patent_app_type] => 1
[patent_app_number] => 7/767742
[patent_app_country] => US
[patent_app_date] => 1991-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5171
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/177/05177001.pdf
[firstpage_image] =>[orig_patent_app_number] => 767742
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/767742 | In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor | Sep 29, 1991 | Issued |
Array
(
[id] => 2836677
[patent_doc_number] => 05171569
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1992-12-15
[patent_title] => 'Factor IX preparations uncontaminated by plasma components or pox virus'
[patent_app_type] => 1
[patent_app_number] => 7/764073
[patent_app_country] => US
[patent_app_date] => 1991-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 6
[patent_no_of_words] => 9509
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/171/05171569.pdf
[firstpage_image] =>[orig_patent_app_number] => 764073
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/764073 | Factor IX preparations uncontaminated by plasma components or pox virus | Sep 22, 1991 | Issued |
| 07/730882 | MEDICAL USES OF M-CSF | Sep 12, 1991 | Abandoned |
| 07/757879 | NOVEL BIOPROCESS FOR PREPARING 7-ADCA | Sep 10, 1991 | Abandoned |
| 07/758228 | ANTIVIRAL THERAPY USING THIAZINE DYES | Sep 8, 1991 | Abandoned |
Array
(
[id] => 3462943
[patent_doc_number] => 05391712
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1995-02-21
[patent_title] => 'Non-hemolytic streptolysin O variants'
[patent_app_type] => 1
[patent_app_number] => 7/752428
[patent_app_country] => US
[patent_app_date] => 1991-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 9
[patent_no_of_words] => 15869
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/391/05391712.pdf
[firstpage_image] =>[orig_patent_app_number] => 752428
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/752428 | Non-hemolytic streptolysin O variants | Aug 29, 1991 | Issued |
Array
(
[id] => 3589381
[patent_doc_number] => 05585344
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1996-12-17
[patent_title] => 'Liver-derived receptors for advanced glycosylation endproducts and uses thereof'
[patent_app_type] => 1
[patent_app_number] => 7/749438
[patent_app_country] => US
[patent_app_date] => 1991-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 18
[patent_no_of_words] => 14833
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/585/05585344.pdf
[firstpage_image] =>[orig_patent_app_number] => 749438
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/749438 | Liver-derived receptors for advanced glycosylation endproducts and uses thereof | Aug 22, 1991 | Issued |
Array
(
[id] => 3409508
[patent_doc_number] => 05437976
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1995-08-01
[patent_title] => 'Multi-domain DNA ligands bound to a solid matrix for protein and nucleic acid affinity chromatography and processing of solid-phase DNA'
[patent_app_type] => 1
[patent_app_number] => 7/742856
[patent_app_country] => US
[patent_app_date] => 1991-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 5302
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/437/05437976.pdf
[firstpage_image] =>[orig_patent_app_number] => 742856
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/742856 | Multi-domain DNA ligands bound to a solid matrix for protein and nucleic acid affinity chromatography and processing of solid-phase DNA | Aug 7, 1991 | Issued |
Array
(
[id] => 3092861
[patent_doc_number] => 05298399
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1994-03-29
[patent_title] => 'Gene and process for producing a thermostable urease'
[patent_app_type] => 1
[patent_app_number] => 7/732242
[patent_app_country] => US
[patent_app_date] => 1991-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 7891
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/298/05298399.pdf
[firstpage_image] =>[orig_patent_app_number] => 732242
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/732242 | Gene and process for producing a thermostable urease | Jul 17, 1991 | Issued |
| 07/726640 | IMMUNOTHERAPY OF TUMOR WITH MONOCLONAL ANTIBODY AGAINST THE 17-1A ANTIGEN | Jul 1, 1991 | Abandoned |
Array
(
[id] => 3868184
[patent_doc_number] => 05763197
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1998-06-09
[patent_title] => 'Human hematopoietic stem cell'
[patent_app_type] => 1
[patent_app_number] => 7/720883
[patent_app_country] => US
[patent_app_date] => 1991-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8974
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/763/05763197.pdf
[firstpage_image] =>[orig_patent_app_number] => 720883
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/720883 | Human hematopoietic stem cell | Jun 24, 1991 | Issued |
Array
(
[id] => 2950114
[patent_doc_number] => 05221611
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1993-06-22
[patent_title] => 'ddI immunoassays, derivatives, conjugates and antibodies'
[patent_app_type] => 1
[patent_app_number] => 7/717614
[patent_app_country] => US
[patent_app_date] => 1991-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12359
[patent_no_of_claims] => 48
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/221/05221611.pdf
[firstpage_image] =>[orig_patent_app_number] => 717614
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/717614 | ddI immunoassays, derivatives, conjugates and antibodies | Jun 18, 1991 | Issued |
| 07/709622 | ORAL DOSAGE FORM OF BIOLOGICALLY ACTIVE PROTEINS | Jun 2, 1991 | Abandoned |
| 07/695733 | PROTEINACEOUS COMPOSITIONS HAVING AN ACTIVITY ON ERYTHROPOIESIS | May 5, 1991 | Abandoned |
| 07/695189 | HUMAN NOTCH AND DELTA, BINDING DOMAINS IN TOPORYTHMIC PROTEINS, AND METHODS BASED THEREON | May 2, 1991 | Abandoned |
Array
(
[id] => 2803818
[patent_doc_number] => 05124437
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1992-06-23
[patent_title] => 'Galactosamine substitute of poly-.omega.-substituted-L-glutamic acid (or aspartic acid)'
[patent_app_type] => 1
[patent_app_number] => 7/690496
[patent_app_country] => US
[patent_app_date] => 1991-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 2883
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/124/05124437.pdf
[firstpage_image] =>[orig_patent_app_number] => 690496
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/690496 | Galactosamine substitute of poly-.omega.-substituted-L-glutamic acid (or aspartic acid) | Apr 22, 1991 | Issued |
| 07/687456 | DNA CLONE OF GUAYULE RUBBER PARTICLE PROTEIN | Apr 16, 1991 | Abandoned |
Array
(
[id] => 2951149
[patent_doc_number] => 05221665
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1993-06-22
[patent_title] => 'N-substituted amides'
[patent_app_type] => 1
[patent_app_number] => 7/686918
[patent_app_country] => US
[patent_app_date] => 1991-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 15428
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/221/05221665.pdf
[firstpage_image] =>[orig_patent_app_number] => 686918
[rel_patent_id] =>[rel_patent_doc_number] =>) 07/686918 | N-substituted amides | Apr 15, 1991 | Issued |